Advances in synthetic biology are revolutionizing medicine across a range of modalities and disease areas. By making biology easier to engineer, Ginkgo can help our customers improve the efficacy and safety of the next generation of cell therapies.

In this virtual event, we'll explore the Ginkgo foundry's capabilities in cell therapy, including CAR-T. We offer services in three categories, all supported by our industry-leading platform for DNA assembly, agile automation, and high-throughput screening in clinically relevant assays.

- Novel CAR Designs. Ginkgo has constructed libraries of novel ICDs, ECDs and armoring domains to optimize your CAR's performance. We can perform pooled CAR screening in primary immune cells, offering both off-the-shelf assays and bespoke application-specific assays.

- Regulatory Elements. Tissue-specific promoters can improve the efficacy or the safety profile of your cell therapy. Strong and stable expression elements can increase potency. Ginkgo can assemble and screen large libraries of custom regulatory sequences.

- iPSC Engineering. Ginkgo's platform can support the development of allogeneic cells and therapeutics for more predictive in vitro models. We offer promoter screening and safe harbor discovery for the advanced disease models enabled by iPSCs.

Learn more at ginkgobioworks.com/offerings/biopharmaceutical/
or e-mail us at celltherapy@ginkgobioworks.com

свернуть